Lynk Pharmaceuticals reports long-term Phase III data for rheumatoid arthritis drug

Lynk Pharmaceuticals announced positive long-term data from a Phase III trial evaluating zemprocitinib in patients with moderate-to-severe rheumatoid arthritis. The study focused on individuals who had an inadequate response to biologic disease-modifying antirheumatic drugs (bDMARDs).

The results provide insights into the safety and efficacy profile of the drug over an extended treatment period. Data indicated that participants receiving the treatment maintained clinical improvements, meeting the study's primary endpoints regarding disease activity reduction.

Rheumatoid arthritis remains a significant challenge for patients who fail to respond to traditional biologic therapies. The clinical findings represent a step for Lynk Pharmaceuticals as it seeks to address this unmet need in the autoimmune sector.

Regulatory filings based on these late-stage trial results are expected to follow, subject to final data analysis and oversight. The company plans to submit these findings for peer review and inclusion in upcoming medical conferences.